Diabetologia

, Volume 57, Issue 6, pp 1204–1208 | Cite as

Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals

  • Anna Fenzl
  • Bianca K. Itariu
  • Lana Kosi
  • Monika Fritzer-Szekeres
  • Alexandra Kautzky-Willer
  • Thomas M. Stulnig
  • Florian W. Kiefer
Short Communication

Abstract

Aims/hypothesis

The newly identified liver- and fat-derived hormone, betatrophin, has recently been linked to insulin resistance and pancreatic beta cell growth in mice. These preclinical findings have suggested betatrophin as a potential candidate for novel glucose-lowering treatment concepts involving beta cell regeneration. However, the role of betatrophin in human insulin resistance and type 2 diabetes is currently unknown. Hence, the aim of this study was to investigate circulating betatrophin concentrations in two distinct cohorts with insulin resistance.

Methods

Betatrophin concentrations were analysed in (1) age- and sex-matched lean (n = 20) and morbidly obese individuals (n = 19), and (2) age-, sex- and BMI-matched non-diabetic (n = 19) and type 2 diabetic individuals (n = 18).

Results

Betatrophin concentrations did not differ between lean and morbidly obese or between non-diabetic and type 2 diabetic participants. No association was found with variables of beta cell function and glucose homeostasis. However, betatrophin did correlate significantly with plasma atherogenic lipids including total cholesterol, LDL-cholesterol and apolipoprotein B in morbidly obese and type 2 diabetic patients but not in controls. Insulin-resistant individuals with hypercholesterolaemia (≥5.2 mmol/l) had significantly higher betatrophin concentrations than those with normal cholesterol (<5.2 mmol/l).

Conclusions/interpretation

Betatrophin is a recently identified hormone, the circulating concentrations of which are unaltered in human insulin resistance but correlate significantly with atherogenic lipid profiles in high-risk cohorts with morbid obesity or type 2 diabetes. Betatrophin could therefore be a novel pathomechanistic player in dysfunctional lipid metabolism associated with high cardiovascular risk.

Keywords

ANGPTL8 Betatrophin Insulin resistance Lipid metabolism LDL-cholesterol 

Abbreviations

ANGPTL

Angiopoietin-like protein

HDL-C

HDL-cholesterol

LDL-C

LDL-cholesterol

Supplementary material

125_2014_3208_MOESM1_ESM.pdf (84 kb)
ESM Table 1(PDF 83 kb)
125_2014_3208_MOESM2_ESM.pdf (75 kb)
ESM Table 2(PDF 75 kb)
125_2014_3208_MOESM3_ESM.pdf (158 kb)
ESM Fig. 1(PDF 158 kb)

References

  1. 1.
    Yi P, Park JS, Melton DA (2013) Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell 153:747–758PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Lickert H (2013) Betatrophin fuels beta cell proliferation: first step toward regenerative therapy? Cell Metab 18:5–6PubMedCrossRefGoogle Scholar
  3. 3.
    Kugelberg E (2013) Diabetes: betatrophin-inducing beta-cell expansion to treat diabetes mellitus? Nat Rev Endocrinol 9:379PubMedCrossRefGoogle Scholar
  4. 4.
    Ren G, Kim JY, Smas CM (2012) Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab 303:E334–E351PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Zhang R (2012) Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 424:786–792PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang R, Abou-Samra AB (2013) Emerging roles of lipasin as a critical lipid regulator. Biochem Biophys Res Commun 432:401–405PubMedCrossRefGoogle Scholar
  7. 7.
    Wang Y, Quagliarini F, Gusarova V et al (2013) Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A 110:16109–16114PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Koster A, Chao YB, Mosior M et al (2005) Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146:4943–4950PubMedCrossRefGoogle Scholar
  9. 9.
    Musunuru K, Pirruccello JP, Do R et al (2010) Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 363:2220–2227PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Espes D, Lau J, Carlsson PO (2014) Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia 57:50–53PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Quagliarini F, Wang Y, Kozlitina J et al (2012) Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A 109:19751–19756PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Anna Fenzl
    • 1
  • Bianca K. Itariu
    • 1
    • 2
  • Lana Kosi
    • 1
  • Monika Fritzer-Szekeres
    • 3
  • Alexandra Kautzky-Willer
    • 1
  • Thomas M. Stulnig
    • 1
    • 2
  • Florian W. Kiefer
    • 1
  1. 1.Clinical Division of Endocrinology and Metabolism, Department of Medicine IIIMedical University of ViennaViennaAustria
  2. 2.Christian Doppler-Laboratory for Cardio-Metabolic ImmunotherapyMedical University of ViennaViennaAustria
  3. 3.Clinical Institute for Medical and Chemical Laboratory DiagnosticsMedical University of ViennaViennaAustria

Personalised recommendations